Hydroxyurea (Droxia) vs Hydroxyurea (Xromi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Sickle Cell Disease

Shared mechanism: Ribonucleotide reductase · full Sickle Cell Disease pipeline

Hydroxyurea (Droxia)

Marketed by Waylis Therapeutics LLC and partners

Approved in Sickle Cell Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Hydroxyurea (Xromi)

Marketed by Nova Laboratories Limited and partners

Approved in Sickle Cell Diseasesmall molecule
Weak signal

NCT03763656 · Phase 1/2 · completed

This was a single-group, open-label study of 33 children, with 32 receiving oral hydroxyurea and no placebo or active comparator. Its primary outcomes were pharmacokinetic measurements rather than clinical outcomes, so the findings provide limited evidence about hydroxyurea’s clinical effectiveness.

No aligned efficacy figure on record for this race.

Results for Sickle Cell Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Hydroxyurea (Droxia): registry results are on file for Sickle Cell Disease, but their comparison mappings are not yet available.

Hydroxyurea (Xromi): registry results are on file for Sickle Cell Disease, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hydroxyurea (Droxia)'s landscape · Hydroxyurea (Xromi)'s landscape